Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company focusing on oncology drug candidates for difficult-to-treat and treatment-resistant cancers, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.

Key details of Apollomics' presentation:

• Date and Time: Tuesday, August 14, 2024, at 9:30 am ET
• Location: InterContinental Boston Hotel
• Presenter: Matthew Plunkett, PhD, Chief Financial Officer

The company management will be available for one-on-one meetings during the conference. Interested investors can contact their Canaccord Genuity representative to schedule meetings. A webcast link for the presentation will be available on the company's website under the Investors section on the Events page.

FOSTER CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the Company management will be presenting at the Canaccord Genuity 44^th Annual Growth Conference taking place on August 13-15, 2024 in Boston, MA.

Canaccord Genuity 44^th Annual Growth Conference

Format: Company presentation
Presentation Date & Time: Tuesday, August 14, 2024 at 9:30 am ET
Location: InterContinental Boston Hotel
Presenter: Matthew Plunkett, PhD, Chief Financial Officer of Apollomics
Webcast: Click here

Management will be available for one-on-one meetings during the conference. Interested investors should contact their Canaccord Genuity representative to request meetings. A link to access company presentation, when available, will be posted to Company website on the Events page under the Investors section.

About Apollomics Inc. 

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead programs include its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China. For more information, please visit www.apollomicsinc.com.

Investor Contact:

Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363
eric@lifesciadvisors.com

FAQ

When is Apollomics (APLM) presenting at the Canaccord Genuity 44th Annual Growth Conference?

Apollomics (APLM) is presenting on Tuesday, August 14, 2024, at 9:30 am ET at the Canaccord Genuity 44th Annual Growth Conference.

Who will be presenting for Apollomics (APLM) at the Canaccord Genuity conference?

Matthew Plunkett, PhD, Chief Financial Officer of Apollomics, will be presenting at the Canaccord Genuity conference.

Where can investors access the webcast of Apollomics' (APLM) presentation?

The webcast link for Apollomics' presentation will be available on the company's website on the Events page under the Investors section.

What is the focus of Apollomics' (APLM) drug development?

Apollomics focuses on developing oncology drug candidates to address difficult-to-treat and treatment-resistant cancers.

How can investors arrange meetings with Apollomics (APLM) management at the conference?

Interested investors should contact their Canaccord Genuity representative to request one-on-one meetings with Apollomics management during the conference.